Literature DB >> 18630467

Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma.

Kenichi Ohtsuki1, Fumikazu Koyama, Tomomi Tamura, Yasunori Enomoto, Hisao Fujii, Tomohide Mukogawa, Tadashi Nakagawa, Kazuaki Uchimoto, Shinji Nakamura, Akitaka Nonomura, Yoshiyuki Nakajima.   

Abstract

BACKGROUND: Tumor 'budding' of colorectal carcinoma along the invasive margin has been associated with increased malignant potential. This study investigated the possible prognostic significance of budding in invasive colorectal carcinoma. PATIENTS AND METHODS: Specimens resected from 149 patients who underwent potentially curative surgery for invasive colorectal carcinoma were studied. Budding was defined according to Ueno's criteria; budding intensity was assessed by examination of hematoxylin-eosin (HE)-stained specimens and immunohistochemical (IHC)-stained specimens using anti-cytokeratin antibody and anti-lymphatic vessel antibody.
RESULTS: Immunohistochemical analysis identified many more budding foci that were not detectable by examination of HE-stained specimens. Multivariate analyses revealed that budding identified using immunohistochemical staining was a significant prognostic marker for disease-free survival and there was significant correlation between budding and microlymphatic vessel infiltration at the invasive tumor front.
CONCLUSION: Budding, particularly as assessed with immunohistochemical staining, is a useful predictor of poor prognosis in patients with invasive colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630467

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  30 in total

Review 1.  Tumour budding in colorectal cancer: what do we know and what can we do?

Authors:  Linde De Smedt; Sofie Palmans; Xavier Sagaert
Journal:  Virchows Arch       Date:  2015-11-27       Impact factor: 4.064

2.  Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance?

Authors:  Benedikt Martin; Eva Schäfer; Elzbieta Jakubowicz; Patrick Mayr; Regina Ihringer; Matthias Anthuber; Gerhard Schenkirsch; Tina Schaller; Bruno Märkl
Journal:  Virchows Arch       Date:  2018-04-06       Impact factor: 4.064

3.  Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer

Authors:  Richard Garfinkle; Lawrence Lee; Marylise Boutros; Marie-Josee Cardin; Alan Spatz; Nancy Morin
Journal:  Can J Surg       Date:  2019-10-01       Impact factor: 2.089

Review 4.  Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis.

Authors:  F Petrelli; E Pezzica; M Cabiddu; A Coinu; K Borgonovo; M Ghilardi; V Lonati; D Corti; S Barni
Journal:  J Gastrointest Cancer       Date:  2015-09

5.  Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study.

Authors:  Viktor H Koelzer; Inti Zlobec; Martin D Berger; Gieri Cathomas; Heather Dawson; Klaus Dirschmid; Marion Hädrich; Daniel Inderbitzin; Felix Offner; Giacomo Puppa; Walter Seelentag; Beat Schnüriger; Luigi Tornillo; Alessandro Lugli
Journal:  Virchows Arch       Date:  2015-02-21       Impact factor: 4.064

Review 6.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Authors:  Alessandro Lugli; Richard Kirsch; Yoichi Ajioka; Fred Bosman; Gieri Cathomas; Heather Dawson; Hala El Zimaity; Jean-François Fléjou; Tine Plato Hansen; Arndt Hartmann; Sanjay Kakar; Cord Langner; Iris Nagtegaal; Giacomo Puppa; Robert Riddell; Ari Ristimäki; Kieran Sheahan; Thomas Smyrk; Kenichi Sugihara; Benoît Terris; Hideki Ueno; Michael Vieth; Inti Zlobec; Phil Quirke
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

7.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

8.  Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.

Authors:  Shigenobu Tatsumi; Hiroshi Matsuoka; Yumi Hashimoto; Kohei Hatta; Kotaro Maeda; Shingo Kamoshida
Journal:  Int J Clin Exp Pathol       Date:  2013-12-09

Review 9.  Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  Oncotarget       Date:  2010-11

10.  Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met.

Authors:  Keisuke Satoh; Satoshi Nimura; Mikiko Aoki; Makoto Hamasaki; Kaori Koga; Hiroshi Iwasaki; Yuichi Yamashita; Hiroaki Kataoka; Kazuki Nabeshima
Journal:  Cancer Sci       Date:  2014-10-09       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.